Investors in German B2B specialist TAKKT AG (ETR:TTK) have faced a punishing three years, with total shareholder returns plummeting 68%. As revenue declines and the share price continues to slide, we examine the fundamentals behind the downturn and what it signals for the company's future.
Igor Runets, founder and CEO of Russia's largest Bitcoin mining operator BitRiver, has been detained and placed under house arrest on charges of large-scale tax evasion. The case unfolds against a backdrop of Western sanctions and operational challenges for the once-dominant firm.
As the FTSE 100 hits record highs, a broader rally in UK mid and small-cap indices is prompting a strategic rethink. Analysts debate whether these long-neglected shares, now showing historic undervaluation, are poised for a major comeback.
At 77, Jane Perry's £2 million ISA portfolio stands as a testament to a simple, disciplined investment strategy begun in the 1980s. Her story challenges the gender investment gap and offers a blueprint for long-term wealth building.
Bitcoin experienced a sharp, V-shaped recovery after briefly tumbling near $74,000, a swing exacerbated by critically thin market liquidity. The move liquidated over half a billion dollars in leveraged positions, underscoring heightened volatility as traders navigate a market lacking depth.
The iconic pottery maker reports encouraging sales growth and a renewed focus on its craft heritage, aiming to return to profitability next year after a period of job cuts and industry-wide challenges.
Amid broader market uncertainty, companies with high insider ownership and robust earnings forecasts can signal aligned interests and resilience. We examine three such UK-listed firms, from a gold miner to a convenience food giant, where those running the show have significant personal stakes.
While Stabilus SE's recent profit figures appeared subdued, a closer examination reveals underlying strength and potential for a rebound, as the market's positive reaction suggests.
Precious metals continue their sharp retreat from January's record highs, with silver leading the decline as market sentiment shifts following key U.S. policy signals.
The Singapore-listed food company has turned profitable after years of losses, with a 12% return on capital employed and a significant expansion in its capital base—key indicators watched by investors seeking compounding growth stocks.
Lucky Strike Entertainment's stock has tumbled nearly 24% over the past year, raising critical questions about its true worth. We analyze whether the current price reflects underlying value or signals an overextended valuation.
Cardiac monitoring specialist iRhythm has finalized a significant corporate restructuring, creating a new parent company to serve as its publicly listed entity on Nasdaq. The move is seen as a strategic step to streamline governance and provide operational flexibility as the company expands its AI-driven health platform.
Shares of insulin pump maker Tandem Diabetes Care have plummeted over 80% in five years, trading near $20. A deep dive into valuation metrics suggests the stock may now be modestly undervalued, but significant risks and competitive pressures remain.
Shares of PROG Holdings (PRG) have rallied sharply in recent months, prompting investors to scrutinize whether the fintech company's current valuation reflects its underlying fundamentals or is simply riding a wave of market momentum.
After a recent pullback, Landstar System's (LSTR) shares present a complex valuation picture. While short-term momentum has improved, the stock trades at a significant premium to industry P/E ratios, raising questions about its growth prospects amid a mixed freight demand environment.
Shares of Advantest Corp. have surged nearly 200% in the past year, riding the AI and advanced chipmaking wave. As the stock trades near record highs, investors are grappling with a critical question: has the rally run too far, too fast?
Advanced Energy Industries (AEIS) transitions from the S&P 600 to the S&P 400 index, a move that reflects its evolving market stature and is set to alter its visibility among institutional investors and index-tracking funds.
Amid a patchy eurozone recovery, investors are scanning the market's fringes for potential. We spotlight three small-cap stocks from Norway and Sweden, each navigating unique challenges while showing flashes of promise for the discerning, risk-tolerant investor.
Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.
As transatlantic tensions simmer, a renewed push to bring home Germany's gold stored in New York vaults sparks debate over financial security, political symbolism, and Cold War-era trust.
